BridgeBio Pharma, Inc. — Form SCHEDULE 13D/A
Filed August 17, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 8/100
What the filing says
This is an amended Schedule 13D filing disclosing directors of KKR Co. Inc. The document lists 11 directors including co-founders Henry Kravis and George Roberts, co-CEOs Joseph Bae and Scott Nuttall, and several independent directors with backgrounds in major corporations. No ownership changes, transactions, or material corporate events involving BridgeBio are disclosed in this exhibit.
Why this rating
Routine disclosure amendment with no direct business impact on BridgeBio; administrative filing only.
See more from August 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.